Alvio Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.27 Cr
as on 24-10-2024
- Company Age 16 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.54 Cr
as on 24-10-2024
- Satisfied Charges ₹ 2.50 M
as on 24-10-2024
- Revenue -11.05%
(FY 2023)
- Profit -230.14%
(FY 2023)
- Ebitda 114.86%
(FY 2023)
- Net Worth -12.85%
(FY 2023)
- Total Assets -16.93%
(FY 2023)
About Alvio Pharmaceuticals
The Corporate was formerly known as Akshay Vyapaar Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.27 Cr.
The company currently has active open charges totaling ₹9.54 Cr. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Manish Dudhwewala and Nilesh Dudhwewala serve as directors at the Company.
- CIN/LLPIN
U24100GJ2008PTC092271
- Company No.
092271
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jan 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Alvio Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Dudhwewala  | Whole-Time Director | 07-Feb-2008 | Current |
| Nilesh Dudhwewala | Whole-Time Director | 07-Oct-2015 | Current |
Financial Performance of Alvio Pharmaceuticals.
Alvio Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.05% decrease. The company also saw a substantial fall in profitability, with a 230.14% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alvio Pharmaceuticals?
In 2023, Alvio Pharmaceuticals had a promoter holding of 95.63% and a public holding of 4.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Salud Care (India) LimitedActive 21 years 1 monthManish Dudhwewala and Nilesh Dudhwewala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Oct 2023 | ₹1.50 M | Open |
Others Creation Date: 24 Feb 2022 | ₹4.00 Cr | Open |
Others Creation Date: 22 Feb 2022 | ₹6.40 M | Open |
How Many Employees Work at Alvio Pharmaceuticals?
Alvio Pharmaceuticals has a workforce of 171 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alvio Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alvio Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
